TAM
SRPT icon

Tyers Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Tyers Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$16K Buy
208
+64
+44% +$7.56K ﹤0.01% 965
2019
Q2 		$22K Hold
144
– – ﹤0.01% 960
2019
Q1 		$17K Buy
144
+16
+13% +$2.06K ﹤0.01% 959
2018
Q4 		$14K Buy
+128
New +$16K ﹤0.01% 926

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tyers Asset Management's SRPT Position: Q3 2019 in Review

Tyers Asset Management increased its Sarepta Therapeutics (SRPT) stake by 44% in Q3 2019, buying an estimated $7.56K and bringing the position to 208 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Tyers Asset Management first reported a position in SRPT in Q4 2018 and has held it in 4 quarters since. The position peaked at $22K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Tyers Asset Management held 208 shares of Sarepta Therapeutics worth $16K as of Q3 2019.
  • Tyers Asset Management bought 64 Sarepta Therapeutics shares in Q3 2019, an estimated $7.56K.
  • Sarepta Therapeutics made up ﹤0.01% of Tyers Asset Management's portfolio in Q3 2019, its #965 holding.
  • Tyers Asset Management first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tyers Asset Management's Sarepta Therapeutics position peaked at $22K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.